U S Physical Therapy Inc
USPH- Exchange
- NYSE
- Industry
- Services-Health Services
- SEC CIK
- 0000885978
In the last 90 days, U S Physical Therapy Inc insiders filed 1 open-market purchase and 1 sale; 235 institutions reported holding it in 13F filings for Q3 2026, worth $1.46B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:34 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | Feb 28, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Revenue | $781.0M | $671.3M | $604.8M | $553.1M | $495.0M |
| Gross profit | $149.7M | $123.9M | $121.5M | $112.0M | $117.2M |
| Selling, general and administrative | $69.3M | $58.3M | $52.0M | $46.1M | $46.5M |
| Operating income | $86.7M | $63.2M | $52.1M | $56.8M | $70.6M |
| Income tax | $19.8M | $14.6M | $12.2M | $12.2M | $15.3M |
| Net income | $39.6M | $31.4M | $28.2M | $32.2M | $40.8M |
| EPS, basic | $1.42 | $1.84 | $1.28 | $2.25 | $2.41 |
| EPS, diluted | $1.42 | $1.84 | $1.28 | $2.25 | $2.41 |
| Weighted shares, basic | 15.2M | 15.1M | 14.2M | 13.0M | 12.9M |
| Weighted shares, diluted | 15.2M | 15.1M | 14.2M | 13.0M | 12.9M |
| Margins and growth | |||||
| Gross margin | 19.2% | 18.5% | 20.1% | 20.3% | 23.7% |
| Operating margin | 11.1% | 9.4% | 8.6% | 10.3% | 14.3% |
| Net margin | 5.1% | 4.7% | 4.7% | 5.8% | 8.2% |
| Revenue growth, year over year | +16.3% | +11.0% | +9.3% | +11.7% | +17.0% |
| Net income growth, year over year | +26.0% | +11.3% | −12.2% | −21.2% | +16.0% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025! | FY2024! | FY2023! | FY2022! | FY2021! |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | Feb 28, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Cash and equivalents | $35.6M | $41.4M | $152.8M | $31.6M | $28.6M |
| Accounts receivable | $64.2M | $59.0M | $51.9M | $51.9M | $46.3M |
| Total current assets | $140.0M | $137.6M | $233.4M | $111.3M | $95.2M |
| Property, plant and equipment | $35.7M | $32.1M | $26.1M | $24.7M | $23.0M |
| Goodwill | $692.4M | $667.2M | $509.6M | $494.1M | $434.7M |
| Intangible assets | $172.9M | $179.3M | $109.7M | $108.8M | $86.4M |
| Total assets | $1.20B | $1.17B | $997.2M | $858.2M | $749.4M |
| Short-term debt | $9.87M | $11.0M | $7.69M | $7.86M | $830.0K |
| Total current liabilities | $139.0M | $116.3M | $102.2M | $85.5M | $83.5M |
| Long-term debt | $152.6M | $142.5M | $139.0M | $175.8M | $117.6M |
| Total liabilities | $433.8M | $408.4M | $345.0M | $373.6M | $297.0M |
| Shareholders' equity | $476.9M | $490.0M | $477.4M | $317.1M | $297.2M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | Feb 28, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating cash flow | $75.1M | $74.9M | $82.0M | $58.5M | $76.4M |
| Capital expenditures | $14.1M | $9.19M | $9.29M | $8.25M | $8.20M |
| Free cash flow | $61.0M | $65.8M | $72.7M | $50.3M | $68.2M |
| Depreciation and amortization | $22.4M | $18.7M | $15.7M | $14.7M | $11.6M |
| Stock-based compensation | $8.27M | $7.82M | $7.24M | $7.26M | $7.87M |
| Dividends paid | $27.4M | $26.5M | $24.1M | $21.3M | $18.8M |
| Share buybacks | $5.57M | – | – | – | – |
| Investing cash flow | -$36.7M | -$149.4M | -$45.0M | -$81.3M | -$124.1M |
| Financing cash flow | -$44.1M | -$37.0M | $84.3M | $25.8M | $43.4M |
| Net change in cash | -$5.79M | -$111.5M | $121.2M | $3.03M | -$4.35M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.1% | 1.2% | 1.2% | 1.3% | 1.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 5, 2026 | 14.9M | −1.8% | SEC |
| Aug 7, 2026 | 14.9M | −1.9% | SEC |
| May 8, 2026 | 15.2M | +0.2% | SEC |
| Feb 23, 2026 | 15.1M | −0.5% | SEC |
| Nov 7, 2025 | 15.2M | +0.7% | SEC |
| Aug 8, 2025 | 15.2M | +0.8% | SEC |
| May 9, 2025 | 15.2M | +0.8% | SEC |
| Mar 3, 2025 | 15.2M | +0.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.